Vcd Medical S.R.L. appears in FDA records as the applicant on a single premarket notification, K260677, for a device named Vessel Closure Device (VCD177213P). The filing was received on 2 March 2026 and decided on 17 September 2026 as Substantially Equivalent under the Traditional pathway, with a Summary statement and no third-party review. The company's own site describes the VEnice™ Vein Closure Device as its FDA-cleared product and frames the organization around minimally invasive treatment of diseased venous vessels. [1][2][5]
The documented FDA filing
K260677 lists Vcd Medical S.R.L. as applicant, with a contact named Francesco Piccagli and an address in Brescia, Italy. The device is recorded as Vessel Closure Device (VCD177213P) under product code FZP, regulation 878.4300, classification name Clip, Implantable, device class 2. The regulation medical specialty is General and Plastic Surgery, while the 510(k) review panel is Cardiovascular. The decision code is SESE, described as Substantially Equivalent, and the clearance type is Traditional. [1][2][7]
The supplied portfolio snapshot, retrieved 20 November 2026, links one record to this company, all under the 510(k) pathway, with a decision count of one SESE. The record sample contains that same single entry, so the sample decision count also reads one SESE. These figures describe the supplied filings as of that date and are not measures of total company sales, total portfolio or safety performance. [1]
What the device is
VCD Medical's technology page describes VEnice™ as delivering an implantable clip through a low-profile cannula under ultrasound guidance, with distal and proximal clip elements working together to mechanically close targeted superficial and perforator veins. The page states the approach uses no thermal energy, adhesives or tumescent anesthesia, and pairs a handheld applicator with the low-profile cannula. The home page repeats percutaneous, ultrasound-guided placement and non-thermal, non-adhesive mechanical closure for superficial and perforator venous vessels. [3][4]
A published US patent application, US2023/0181193A1, names VCD Medical S.R.L. as applicant and Gastone Bergamaschi as inventor, with a filing date of 15 December 2021 and publication on 15 June 2023. Its abstract describes a percutaneous device for closing blood vessels with a main body housing a distal clip and a proximal clip connected by a tie rod, plus an abutment element and a handle for maneuvering the clips, the abutment element and the tie rod. The description adds that the tie rod sits inside the clip housings when both clips are inserted in the main body. [6]
Company statements and scope
The company's About page describes VCD Medical as a medical technology company developing minimally invasive technologies for diseased venous vessels, including the FDA-cleared VEnice™ Vein Closure Device, and states a mission to expand treatment options in venous care. That page lists Francesco Piccagli as Chief Executive Officer, Denna Babul as US General Manager, Achille Sina as Chief Technical Officer and Davide Zanetti as R&D Manager, and names clinical advisors and board members. These are company-published statements attributed to VCD Medical. [5]
The home page states that VEnice™ has been evaluated in clinical studies of vessel closure, durability, safety and patient outcomes and describes use across superficial, tributary and perforating veins. No study results, outcome figures or patient-selection criteria appear in the public documents, and no parent company, brand owner or headquarters is verified beyond the Brescia address recorded in the FDA filing, which is a filing address rather than a confirmed headquarters. [1][4]

